Literature DB >> 9504461

Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese.

J Uwabo1, M Soma, T Nakayama, K Kanmatsuse.   

Abstract

An impaired synthesis of nitric oxide (NO) by the vascular endothelium has been implicated in the pathogenesis of essential hypertension (EH). The possible association between a variable number of tandem repeats (VNTR) polymorphism in intron 4 of the endothelial constitutive NO synthase (ecNOS) gene and EH in Japanese subjects was investigated. A total of 123 individuals with EH and 120 normotensive control subjects were studied. The VNTR region of the ecNOS gene was amplified by the polymerase chain reaction to determine the number of repeats, and the allele frequencies were compared between the hypertensive and normotensive groups. Two alleles, containing four and five repeats, were identified. The overall distributions of allele frequencies differed significantly between the two groups, with the four-repeat allele more frequent in the EH group than in the normotensive group (P = .00027, odds ratio = 4.0). The four-repeat allele of the ecNOS gene was thus associated with EH and may be a genetic marker of this disease in Japanese subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9504461     DOI: 10.1016/s0895-7061(97)00419-6

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  Racial differences in nitric oxide-dependent vasorelaxation.

Authors:  Eugenia Mata-Greenwood; Dong-Bao Chen
Journal:  Reprod Sci       Date:  2008-01       Impact factor: 3.060

2.  Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease.

Authors:  R Alvarez; V Alvarez; C H Lahoz; C Martínez; J Peña; J M Sánchez; L M Guisasola; J Salas-Puig; G Morís; J A Vidal; R Ribacoba; B B Menes; D Uría; E Coto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 3.  Nitric oxide, nitric oxide synthase, and hypertensive vascular disease.

Authors:  R Busse; I Fleming
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

4.  Genetic polymorphisms and endothelial dysfunction in patients with essential hypertension: a cross-sectional case-control study.

Authors:  S Demirel; V Akkaya; N Cine; H Oflaz; E Yekeler; S Ozturk; T J Cleophas; F Fici
Journal:  Neth Heart J       Date:  2005-04       Impact factor: 2.380

Review 5.  Genes and abdominal aortic aneurysm.

Authors:  Irene Hinterseher; Gerard Tromp; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2010-12-13       Impact factor: 1.466

6.  High risk of essential hypertension in males with intron 4 VNTR polymorphism of eNOS gene.

Authors:  Sushma Patkar; B H Charita; C Ramesh; T Padma
Journal:  Indian J Hum Genet       Date:  2009-05

7.  Association of endothelial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans.

Authors:  K-W Park; K-H You; S Oh; I-H Chae; H-S Kim; B-H Oh; M-M Lee; Y-B Park
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

8.  Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease and rheumatic diseases with vasculitis.

Authors:  J U Kim; H K Chang; S S Lee; J W Kim; K T Kim; S W Lee; W T Chung
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension.

Authors:  Wenquan Niu; Yue Qi
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

10.  Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients: effect of ecNOS polymorphism on left ventricular hypertrophy.

Authors:  Ayhan Olcay; C Gokhan Ekmekci; Ugur Ozbek; Murat Sezer; Cem Barcin; Erol Arslan; Bilal Boztosun; Yilmaz Nisanci
Journal:  Cardiovasc Ultrasound       Date:  2006-08-21       Impact factor: 2.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.